Kintor hits back at press criticism of COVID drug with US trial updateThe China-based biotech Kintor has hit back at press criticism of its potential COVID drug proxalutamide, releasing further Share XKintor hits back at press criticism of COVID drug with US trial updatehttps://pharmaphorum.com/news/kintor-hits-back-at-press-criticism-of-covid-drug-with-us-trial-update/
Scepticism in press over Kintor’s COVID-19 US drug trialChina’s Kintor Pharmaceutical has begun late-stage US clinical development of its potential COVID drug proxalutamide – but there Share XScepticism in press over Kintor’s COVID-19 US drug trialhttps://pharmaphorum.com/news/doubts-emerge-over-kintors-covid-19-us-drug-trial/
